Kenya - English - Pharmacy and Poisons Board

q pharma dmcc unit no: 2681 dmcc business centre level no. 1 - empagaliflozin 25mg + linagliptin 5mg+metformin… - coated tablet - empagaliflozin 25mg + linagliptin 5mg+metformin… - linagliptin

India - English - Central Drugs Standard Control Organization

wilshire - lycopene,vit.a,vit.c,vit.e,zinc sulph.,selenium - cap - 2000mg,2500iu.,50mg,10mg,45mg,70mg - 10

India - English - Central Drugs Standard Control Organization

wilshire - calcium citrate,vit.d3 - tab - 10*10

India - English - Central Drugs Standard Control Organization

wilshire - cyproheptadine hcl.,sorbitol sol.,tricholine citrate - syr - 2,3.575,275;mg - syr

India - English - Central Drugs Standard Control Organization

wilshire - rabeprazole,domperidone - cap - 20,30;mg - 10*10

United States - English - NLM (National Library of Medicine)

wilshire pharmaceuticals, inc. - perphenazine (unii: fta7xxy4ez) (perphenazine - unii:fta7xxy4ez) - perphenazine 2 mg - perphenazine is indicated for use in the treatment of schizophrenia and for the control of severe nausea and vomiting in adults. perphenazine has not been shown effective for the management of behavioral complications in patients with mental retardation. perphenazine products are contraindicated in comatose or greatly obtunded patients and in patients receiving large doses of central nervous system depressants (barbiturates, alcohol, narcotics, analgesics, or antihistamines); in the presence of existing blood dyscrasias, bone marrow depression, or liver damage; and in patients who have shown hypersensitivity to perphenazine products, their components, or related compounds. perphenazine products are also contraindicated in patients with suspected or established subcortical brain damage, with or without hypothalamic damage, since a hyperthermic reaction with temperatures in excess of 104°f may occur in such patients, sometimes not until 14 to 16 hours after drug administration. total body ice-packing is recomme

United States - English - NLM (National Library of Medicine)

wilshire pharmaceuticals, inc. - dextroamphetamine sulfate (unii: jj768o327n) (dextroamphetamine - unii:tz47u051fi) - dextroamphetamine sulfate 5 mg - dextroamphetamine sulfate tablets, usp are indicated for: known hypersensitivity to amphetamine products. during or within 14 days following the administration of monoamine oxidase inhibitors (hypertensive crises may result). dextroamphetamine sulfate tablets are a schedule ii controlled substance. dextroamphetamine sulfate has a high potential for abuse and misuse which can lead to the development of a substance use disorder, including addiction (see warnings). dextroamphetamine sulfate can be diverted for non-medical use into illicit channels or distribution. abuse is the intentional non-therapeutic use of a drug, even once, to achieve a desired psychological or physiological effect. misuse is the intentional use, for therapeutic purposes, of a drug by an individual in a way other than prescribed by a health care provider or for whom it was not prescribed. drug addiction is a cluster of behavioral, cognitive, and physiological phenomena that may include a strong desire to take the drug, difficulties in con

United States - English - NLM (National Library of Medicine)

wilshire pharmaceuticals, inc. - lamotrigine (unii: u3h27498ks) (lamotrigine - unii:u3h27498ks) - lamotrigine 25 mg

United States - English - NLM (National Library of Medicine)

wilshire pharmaceuticals inc. - erythromycin ethylsuccinate (unii: 1014ksj86f) (erythromycin - unii:63937kv33d) - erythromycin 200 mg in 5 ml - to reduce the development of drug-resistant bacteria and maintain the effectiveness of erythromycin ethylsuccinate and other antibacterial drugs, erythromycin ethylsuccinate should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. when culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. in the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. erythromycin ethylsuccinate is indicated in the treatment of infections caused by susceptible strains of the designated organisms in the diseases listed below: upper respiratory tract infections of mild to moderate degree caused by streptococcus pyogenes , streptococcus pneumoniae , or haemophilus influenzae (when used concomitantly with adequate doses of sulfonamides, since many strains of h. influenza e are not susceptible to the erythromycin concentrati

United States - English - NLM (National Library of Medicine)

wilshire pharmaceuticals, inc. - nitroglycerin (unii: g59m7s0ws3) (nitroglycerin - unii:g59m7s0ws3) - nitroglycerin 400 ug